naa a22 4500 51078190X CHVBK 20180411083250.0 cr unu---uuuuu 180411e20130701xx s 000 0 eng 10.1007/s11414-013-9329-z doi (NATIONALLICENCE)springer-10.1007/s11414-013-9329-z Healthcare Cost Reductions Associated with the Use of LAI Formulations of Antipsychotic Medications Versus Oral Among Patients with Schizophrenia [Elektronische Daten] [Jay Lin, Bruce Wong, Steve Offord, Dario Mirski] Real-world medication adherence and healthcare costs of patients with schizophrenia initiating long-acting injectable (LAI) vs. oral antipsychotics were compared. Patients with schizophrenia initiating LAI or oral antipsychotics (index event) were identified from MarketScan Commercial and Medicare claims databases and their medication possession ratios (MPR), pre- and post-index costs for inpatient/outpatient care were compared. Of 3,004 patients, 394 initiated LAI antipsychotics and 2,610 oral antipsychotics. Post-index, the mean MPR was greater for the LAI cohort (0.67 ± 0.34 vs. 0.56 ± 0.35; p < 0.001). Schizophrenia-related hospital costs for LAI users were reduced during the follow-up period in comparison to the pre-index period, but were increased for patients using oral antipsychotics (-$5,981 ± $16,554 vs. 758 ± 14,328, p < 0.001). The change in costs of outpatient care also favored LAI medications ($134 ± 8,280 vs. 658 ± 3,260, p = 0.023). Drug costs of LAI antipsychotics were higher ($4,132 ± 4,533 vs. 2,562 ± 2,714, p < 0.001). Schizophrenia patients initiating LAI antipsychotics incur less healthcare costs in comparison to patients initiating oral antipsychotics. National Council for Community Behavioral Healthcare, 2013 Lin Jay Novosys Health, 7 Crestmont CT, 08822, Flemington, NJ, USA aut Wong Bruce University of Pennsylvania, Philadelphia, PA, USA aut Offord Steve Otsuka America Pharmaceutical, Inc, Princeton, NJ, USA aut Mirski Dario Otsuka America Pharmaceutical, Inc, Princeton, NJ, USA aut The Journal of Behavioral Health Services & Research Springer US; http://www.springer-ny.com 40/3(2013-07-01), 355-366 1094-3412 40:3<355 2013 40 11414 https://doi.org/10.1007/s11414-013-9329-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s11414-013-9329-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lin Jay Novosys Health, 7 Crestmont CT, 08822, Flemington, NJ, USA aut NATIONALLICENCE 700 1- Wong Bruce University of Pennsylvania, Philadelphia, PA, USA aut NATIONALLICENCE 700 1- Offord Steve Otsuka America Pharmaceutical, Inc, Princeton, NJ, USA aut NATIONALLICENCE 700 1- Mirski Dario Otsuka America Pharmaceutical, Inc, Princeton, NJ, USA aut NATIONALLICENCE 773 0- The Journal of Behavioral Health Services & Research Springer US; http://www.springer-ny.com 40/3(2013-07-01), 355-366 1094-3412 40:3<355 2013 40 11414 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer